AZD6738, Ceralasertib clinical trials
3 indexed studies · 2 currently recruiting
- RecruitingTherapeutic exploratory (Phase II)
A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
This study is looking into new treatments for advanced cancer with specific genetic changes. It's testing two drugs, AZD6738 and Ceralasertib, to see how well they shrink tumours and if they are safe. It's for adults whose cancer has spread.
For: Advanced Cancer Whose Tumours Contain Molecular AlterationsFrance - CompletedPhase I
Accelerating the development and implementation of DNA damage inhibitor and radiotherapy treatment (with or without immunotherapy) in head and neck squamous cell carcinoma
This UK clinical trial is testing a new drug called ceralasertib alongside standard radiotherapy for head and neck cancer. Doctors want to find out the safest and most effective dose of the drug to help stop cancer cells repairing themselves, without causing unmanageable side effects for patients.
For: Primary head and neck squamous cell carcinoma (HNSCC): laryngeal, hypopharyngeal, oropharyngeal cancerUnited Kingdom · England - Not yet recruitingPHASE1
Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib
This study looks at a new drug called ceralasertib for certain cancers. It aims to understand how the body uses and removes the drug, and how much of it gets into the bloodstream. Participants will stay in hospital for parts of the study.
For: NeoplasmUnited Kingdom